What were the results of SPRINT regarding cardiovascular benefit and mortality in the subgroup of patients with CKD?
In the subgroup with CKD (median albumin-creatinine ratio [ACR]: ), the CV benefit missed significance of P < 0.05 (HR: 0.81; 95% CI: 0.63 1.05), while the mortality benefit was nominally significant. That said, SPRINT was not powered for subgroup analyses, especially given that it ended early because of the substantial CV disease and mortality benefit.